MOTIVATION LETTER The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, functions as a biosensing architecture for addiction liability. My independent research, conducted in Lagos without institutional affiliation, produced three sole-authored preprints on OSF and Zenodo that specify the CCT framework, its formal mathematical basis, and a Bayesian population dynamics model with clinical trial architecture. The model achieved an encoding probability reduction from 0.855 to 0.122, an 85.8 percent reduction, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed using ODE/RK45 and Bayesian MCMC validation. The National Science Foundation Biosensing programme supports the development of novel sensing frameworks that translate biological signals into actionable measurement. My CCT model is precisely such a framework: it treats the conjunctive consolidation of reward and memory traces as a measurable biosignal, then applies a tripartite pharmacological intervention to detect and prevent that encoding. The model is implemented in two computational platforms I built independently. IMPRINT screens addiction liability by simulating the CCT dynamics for individual patients. TOPOLOGIX applies topological data analysis, using persistent homology and bipartite simplicial complexes, to map drug-protein interaction networks and predict off-target effects such as hERG cardiotoxicity. I hold a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, a German equivalent of 1.9, and I am a PCN-licensed pharmacist. My computational skills include Python with scipy, numpy, PyMC for MCMC, and ODE solvers; R; TDA with Ripser and Gudhi; NEURON and Brian2 for neural simulation; AlphaFold, RDKit, ADMET and QSAR for drug discovery; GROMACS and AutoDock for molecular dynamics; and Nextflow and SLURM for HPC pipelines. I built GATE, a BCI neural-stimulation safety evaluation tool released under Apache 2.0. Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard who provided my arXiv endorsement, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the scientific validity of the CCT framework. A provisional patent on the core architecture is scheduled for Q3 2026. A review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol. The NSF Biosensing programme offers the funding and validation needed to transition this independent work into a funded research trajectory. I am applying to MSc programmes at the Medical University of Graz and the University of Graz for an October 2026 start. This grant would support the experimental validation phase of the CCT model, specifically the development of a portable biosensing prototype that translates the mathematical framework into a clinical screening tool for addiction liability in low-resource settings like Nigeria. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction neuroscience: the absence of a quantitative framework that predicts when and how reward and memory signals consolidate into persistent addictive encoding. Current models treat reward processing and memory formation as separate systems. The CCT model unifies them through a tripartite pharmacological architecture that identifies a conjunctive threshold, the point at which dopamine-mediated reward signals and glutamate-dependent memory traces converge to produce stable encoding. Below this threshold, encoding probability drops from 0.855 to 0.122, an 85.8 percent reduction. The model is specified in three preprints. The foundational paper on OSF establishes the neurobiological basis. The formal mathematical specification on OSF provides the differential equations and parameter space. The Bayesian population dynamics paper on Zenodo presents MCMC validation using synthetic clinical trial data. All five pre-registered hypotheses H1 through H5 were confirmed. The model demonstrates super-additivity of 12.8 percentage points, meaning the combined effect of the three pharmacological components exceeds the sum of their individual effects. The NSF Biosensing programme supports the translation of such frameworks into sensing technologies. My research proposes to build a biosensing prototype that operationalizes the CCT model for addiction liability screening. The prototype will use the IMPRINT platform, which I built in Lagos, to simulate patient-specific CCT dynamics from input parameters including dopamine receptor density, glutamate transporter efficiency, and memory consolidation rate constants. The output is a single metric: the conjunctive consolidation probability for a given patient and drug combination. Validation will proceed in three phases. Phase one uses the TOPOLOGIX platform to map drug-protein interaction networks for the three pharmacological components of the CCT model, identifying potential off-target effects through persistent homology analysis of bipartite simplicial complexes. Phase two applies Bayesian MCMC to calibrate the model parameters against existing clinical datasets on addiction relapse rates. Phase three designs a clinical trial architecture, specified in the Zenodo preprint, that tests the prototype against standard addiction liability assessments. The research is grounded in my computational pharmacology training. I built GATE, a BCI neural-stimulation safety evaluation tool released under Apache 2.0. I have experience with molecular dynamics simulations using GROMACS and AutoDock, drug discovery pipelines using AlphaFold and RDKit, and ADMET and QSAR modeling. My work as a research assistant at the Centre for Drug Discovery, Development and Production involved NMDA and insulin docking studies. My bioinformatics research at the Genomic Surveillance of Antimicrobial Resistance project built AMR surveillance pipelines. Nigeria has one of the highest rates of substance use disorders in West Africa, with limited access to screening tools. A portable, low-cost biosensing prototype based on the CCT model would address this gap directly. The NSF Biosensing programme's mission to support sensing technologies that address societal challenges aligns with this translational goal. Endorsements from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar provide the neuroscientific credibility required for this interdisciplinary work. PROJECT NARRATIVE Objective: To develop and validate a portable biosensing prototype that operationalizes the Conjunctive Consolidation Threshold model for addiction liability screening in low-resource clinical settings. Background: Addiction is characterized by the persistent encoding of reward-memory associations that drive compulsive drug-seeking behavior. Existing screening tools rely on self-report questionnaires and clinical interviews, which have limited predictive validity and require trained personnel. The CCT model provides a quantitative alternative: it treats the conjunctive consolidation of dopamine and glutamate signals as a measurable biosignal, then applies a tripartite pharmacological intervention to detect and prevent that encoding. The model has been validated mathematically using ODE/RK45 and Bayesian MCMC, with all five pre-registered hypotheses confirmed. Methods: The biosensing prototype will consist of three components. First, a computational engine running the CCT differential equations, implemented in Python using scipy and numpy, with parameter estimation via PyMC MCMC. Second, a data input module that accepts patient-specific biomarkers including dopamine receptor density estimates from genetic data, glutamate transporter efficiency from blood assays, and memory consolidation rate constants from cognitive tests. Third, a visualization interface that outputs the conjunctive consolidation probability as a single risk score. The prototype will be validated against the IMPRINT platform, which I built to simulate addiction liability using the CCT framework. IMPRINT has been tested on synthetic patient populations generated from the Bayesian population dynamics model. The validation will compare the prototype's risk scores against IMPRINT's outputs for 1,000 simulated patients, with a target correlation coefficient of 0.90 or higher. Expected Outcomes: A working prototype that can be deployed on a standard laptop or tablet, requiring no internet connection. A validation dataset demonstrating the prototype's accuracy against the established IMPRINT platform. A clinical trial protocol, specified in the Zenodo preprint, for testing the prototype against standard addiction liability assessments in Nigerian clinical settings. Broader Impacts: The prototype would provide the first quantitative addiction liability screening tool designed for low-resource settings. Nigeria has fewer than 500 psychiatrists for a population of 220 million, making self-report-based screening impractical. A portable computational biosensing tool could be deployed by community health workers with minimal training. The open-source code, released under Apache 2.0, would allow adaptation to other substance use disorders and cultural contexts. Timeline: Months one through three: prototype development and internal testing. Months four through six: validation against IMPRINT platform and parameter optimization. Months seven through nine: preparation of clinical trial protocol and regulatory approval application. Months ten through twelve: pilot testing with 50 synthetic patient profiles and publication of results. Budget Justification: Funding will support computational resources including cloud computing for MCMC simulations, software licensing for molecular dynamics tools, and publication fees for open-access journals. No laboratory equipment is required as the prototype is entirely computational. A stipend for the applicant as an independent researcher is requested at 2,000 USD per month for twelve months, totaling 24,000 USD. Computational costs are estimated at 5,000 USD. Publication and dissemination costs are estimated at 3,000 USD. Travel for collaboration meetings with endorsers is estimated at 4,000 USD. Total request: 36,000 USD. BUDGET NARRATIVE The total budget request is 36,000 USD for a twelve-month project period. This amount is calculated based on the specific costs of conducting independent computational neuroscience research in Lagos, Nigeria, without institutional overhead. Personnel: 24,000 USD for the applicant as principal investigator. This is calculated at 2,000 USD per month for twelve months. This rate is competitive for early-career independent researchers in Nigeria and reflects the full-time commitment required for prototype development, validation, and clinical trial protocol preparation. No additional personnel are requested as the applicant will conduct all work independently. Equipment: 0 USD. The prototype is entirely computational and will be developed on the applicant's existing laptop. Cloud computing resources are included under other costs. Travel: 4,000 USD. This covers one round-trip flight from Lagos to a collaborating institution for a two-week working visit. The destination will be determined based on availability of endorsers, with priority given to the University of Michigan for collaboration with Kent Berridge or Harvard University for collaboration with Samuel Gershman. Accommodation and per diem are included in this amount. Other Costs: 8,000 USD. This includes 5,000 USD for cloud computing resources, specifically AWS or Google Cloud credits for running Bayesian MCMC simulations on large parameter spaces. The remaining 3,000 USD covers publication fees for two open-access journals, one for the prototype validation paper and one for the clinical trial protocol. No indirect costs are charged as the applicant is an independent researcher without institutional affiliation. Total Direct Costs: 36,000 USD. No indirect costs. CHECKLIST - [ ] Complete NSF Biosensing programme application form on Grants.gov - [ ] Upload motivation letter as supplementary document - [ ] Upload research statement as project description - [ ] Upload project narrative as project summary - [ ] Upload budget narrative as budget justification - [ ] Upload current CV including ORCID, GitHub, and publication list - [ ] Upload three preprints from OSF and Zenodo as evidence of prior work - [ ] Upload letters of endorsement from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar - [ ] Upload proof of B.Pharm degree and PCN license - [ ] Upload proof of provisional patent application scheduled for Q3 2026 - [ ] Verify eligibility for early-career researcher track on NSF Biosensing programme - [ ] Confirm deadline on Grants.gov and set submission reminder EDITOR NOTES - Eligibility risk: The NSF Biosensing programme typically requires U.S. institutional affiliation. Eniola is an independent researcher in Nigeria. Verify whether the programme allows direct applications from non-U.S. individuals without a sponsoring institution. If not, identify a U.S.-based collaborator willing to serve as institutional sponsor, possibly one of the endorsers. - Fact verification: The provisional patent application is scheduled for Q3 2026. Confirm that this date is realistic given the current timeline. If the patent has been filed by the time of application, update the document accordingly. If not, consider whether mentioning a scheduled filing is appropriate for a grant application. - Gap in profile: The applicant's age is 29 and they hold a B.Pharm from 2021. The gap between 2021 and the independent research starting in 2025 is not explained. The application should include a brief note about employment during this period, specifically the National Product Manager role at Synthcare starting March 2026 and the Clinical Pharmacist role at Ramset Pharmacy from January to March 2026. Earlier employment from 2021 to 2025 is not specified and should be clarified. - Missing detail: The budget narrative assumes a twelve-month project period, but the NSF Biosensing programme may have specific duration requirements. Verify the programme guidelines and adjust the timeline and budget accordingly. The total request of 36,000 USD is modest and may need to be scaled up or down based on programme limits. - Collaboration risk: The endorsements from Berridge, Gershman, Daw, and Mattar are listed but no formal letters have been obtained. Confirm that each endorser is willing to write a letter specifically for this NSF application. Gershman's arXiv endorsement is mentioned but does not constitute a letter of support for a grant application.